Fluticasone propionate ointment 0.005

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch of AirDuo™ RespiClick® and its Authorized Generic, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

Initial dose should be based upon previous therapy and asthma severity; consideration should be given to current control of asthma symptoms and risk of future exacerbations:

4 to 11 years:

Fluticasone propionate INHALATION POWDER (Flovent Diskus[R]):
Patients new to ICS: Initial dose: 50 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 100 mcg twice a day
Fluticasone propionate INHALATION AEROSOL (Flovent HFA[R]):
88 mcg via oral inhalation twice a day
Maximum dose: 88 mcg twice a day

12 years or older:

Fluticasone propionate INHALATION AEROSOL (Flovent HFA[R]):
Patients new to ICS: Initial dose: 88 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum Dose: 880 mcg twice a day

Fluticasone propionate INHALATION POWDER (Flovent Diskus[R]):
Patients new to ICS: Initial dose: 100 mcg via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 1000 mcg twice a day

Fluticasone propionate INHALATION POWDER (Armonair Respiclick[R]): One oral inhalation twice a day
-Initial dose for patients new to ICS: 55 mcg (low dose) via oral inhalation twice a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose of 113 mcg (medium dose) or 232 mcg (high dose) via oral inhalation twice a day
Maximum Dose: 232 mcg twice a day

Fluticasone furoate INHALATION POWDER Arnuity Ellipta[R]):
Patients new to ICS: Initial dose: 100 mcg via oral inhalation once a day
-Patients previously receiving ICS as well as patients who have not adequately responded after 2 weeks may be titrated to a higher dose
Maximum dose: 200 mcg once a day

Comments:
-Higher initial doses may be considered in patients with poor asthma control or those who have previously required higher doses of other ICS.
-Inhaled short-acting beta(2)-agonists should be used for immediate relief if symptoms arise between doses.
-Maximum benefit of ICS may not be achieved for up to 2 weeks or longer; if adequate control is not achieved in 2 weeks, may increase dose without exceeding maximum dose.
-After asthma stability has been achieved, titrate to the lowest effective dose to reduce the possibility of side effects.
-Not indicated for the relief of acute bronchospasm.

Use: For the maintenance treatment of asthma as prophylactic therapy.

Fluticasone propionate ointment 0.005

fluticasone propionate ointment 0.005

Media:

fluticasone propionate ointment 0.005fluticasone propionate ointment 0.005fluticasone propionate ointment 0.005fluticasone propionate ointment 0.005fluticasone propionate ointment 0.005